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Abstract
Background: Copper homeostasis proteins ATP7A and ATP7B are assumed to be involved in the
intracellular transport of cisplatin. The aim of the present study was to assess the relevance of sub
cellular localisation of these transporters for acquired cisplatin resistance in vitro. For this purpose,
localisation of ATP7A and ATP7B in A2780 human ovarian carcinoma cells and their cisplatin-
resistant variant, A2780cis, was investigated.
Methods: Sub cellular localisation of ATP7A and ATP7B in sensitive and resistant cells was
investigated using confocal fluorescence microscopy after immunohistochemical staining. Co-
localisation experiments with a cisplatin analogue modified with a carboxyfluorescein-diacetate
residue were performed. Cytotoxicity of the fluorescent cisplatin analogue in A2780 and A2780cis
cells was determined using an MTT-based assay. The significance of differences was analysed using
Student's  t  test or Mann-Whitney test as appropriate, p values of < 0.05 were considered
significant.
Results: In the sensitive cells, both transporters are mainly localised in the trans-Golgi network,
whereas they are sequestrated in more peripherally located vesicles in the resistant cells. Altered
localisation of ATP7A and ATP7B in A2780cis cells is likely to be a consequence of major
abnormalities in intracellular protein trafficking related to a reduced lysosomal compartment in this
cell line. Changes in sub cellular localisation of ATP7A and ATP7B may facilitate sequestration of
cisplatin in the vesicular structures of A2780cis cells, which may prevent drug binding to genomic
DNA and thereby contribute to cisplatin resistance.
Conclusion: Our results indicate that alterations in sub cellular localisation of transport proteins
may contribute to cisplatin resistance in vitro. Investigation of intracellular protein localisation in
primary tumour cell cultures and tumour tissues may help to develop markers of clinically relevant
cisplatin resistance. Detection of resistant tumours in patients may in turn enable individualization
of the chemotherapy in the early stage of treatment.
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Background
Despite the success of cisplatin-based anticancer chemo-
therapy, its application is limited because in most cases,
tumours develop resistance after repeated administrations
of the drug. Acquired cisplatin resistance is a net result of
multiple pathways, which often act simultaneously in a
given cell [1,2]. Furthermore, primary mechanisms that
determine a resistant phenotype vary significantly
between different cancer cell lines [3], and also defects in
drug transport appear to play a major role in development
of resistance [4,5]. The mechanisms mediating uptake,
intracellular transport and efflux of cisplatin remain
largely obscure [6]. In the past decade, a number of stud-
ies have provided evidence that the copper homeostasis
proteins ATP7A and ATP7B are involved [7-10]. These P-
type ATPases have been suggested to either sequester cis-
platin in vesicular structures or to mediate efflux of the
drug [11,12]. Increased expression of ATP7A and ATP7B
has been associated with acquired resistance to cisplatin
in cancer cell line models and in clinical samples
[7,8,11,13,14].
Under basal conditions, when extracellular copper con-
centrations are low, ATP7A and ATP7B are localised in the
trans-Golgi network. Exposure to increased copper levels
results in re-localisation of ATP7A to the plasma mem-
brane and of ATP7B to intracellular vesicular compart-
ments. For both proteins, this re-localisation is reversible
once copper has been removed from the culture medium.
Copper-regulated trafficking of ATP7A and ATP7B is
believed to be important for maintaining copper homeos-
tasis [15-17]. The effect of cisplatin on sub cellular locali-
sation of these copper transporters was studied in cell
lines molecularly engineered to express either ATP7A or
ATP7B. In these cell lines, which exhibited a biologically
relevant degree of resistance, both transporters were
found to localise in the trans-Golgi network in the absence
of cisplatin. Cisplatin exposure triggered re-localisation of
ATP7B (and not ATP7A) from the trans-Golgi to more
peripherally located vesicles [10,18,19]. These findings
suggest that ATP7B mediates cisplatin efflux, while ATP7A
is rather involved in the intracellular sequestration of the
drug [12].
The issue of sub cellular localisation of ATP7A and ATP7B
in cell lines, selected for cisplatin resistance, has not yet
been addressed. Recently, we characterised an A2780/
A2780cis cisplatin-sensitive/resistant human ovarian car-
cinoma cell line pair with respect to cisplatin sensitivity,
drug accumulation and efflux, DNA platination, as well as
expression of copper homeostasis proteins [20]. In the
present study, we have investigated localisation of ATP7A
and ATP7B in these cell lines and found that both proteins
have a different localisation pattern in the resistant cells as
compared to the sensitive cells. Here we discuss the factors
that likely account for changes in sub cellular localisation
of ATP7A and ATP7B and consider relevance of altered
protein localisation for decreased cisplatin sensitivity in
the resistant cell line.
Methods
Materials
Bafilomycin A1, MTT (MTT = 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide), Triton X-100,
bovine serum albumin (BSA), ribonuclease A (RNAse A),
fluorescein isothiocyanate-dextran (FITC-dextran, M =
70000), GelMount™ mounting medium and cis-diam-
minedichloridoplatinum(II) (cisplatin) were obtained
from Sigma (Steinheim, Germany). LysoTracker™ Red
DND-99, Hoechst 33342, ALEXA Fluor™ 488- and ALEXA
Fluor™ 594-conjugated chicken anti-goat antibodies,
NBD-C6-ceramide (6-((N-(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino)hexanoyl)-sphingosine) complexed to BSA,
propidium iodide were ordered form Invitrogen (Karl-
sruhe, Germany). Goat antibodies to ATP7A and ATP7B
were from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). All solvents were reagent grade and were used
as purchased. [{1-([5-(and-6)-carboxyfluorescein diace-
tate]aminomethyl)-1,2-ethylenediamine}dichloridoplat-
inum(II)] (CFDA-Pt) was synthesised according to the
previously published method [21]. Briefly, the protection
Boc (t-butyloxycarbonyl) group of [{1-(t-butyloxycarbo-
nyl)-aminomethyl)-1,2-ethylenediamine}dichloridoplat-
inum(II)] was removed in 0.1 M HCl at 60°C overnight.
The resulting solution was neutralised to pH 7.5 with 2 M
NaOH and allowed to react with 0.9 eq 5-(and-6)-carbox-
yfluorescein diacetate, succinimidyl ester (Invitrogen,
Karlsruhe, Germany), for 15 min at 0°C and subsequently
for 30 min at room temperature in order to obtain the
desired compound. The resulting precipitate was centri-
fuged off and successively washed with water, ethanol end
ether. The product was characterised by 1H and 195Pt NMR
spectroscopy and mass spectrometry.
Cell lines and growth conditions
A2780 and A2780cis (cisplatin-resistant) human ovarian
carcinoma cell lines were grown as monolayers in RPMI-
1640 medium supplemented with 10% foetal calf serum,
L-glutamine, penicillin and streptomycin (Sigma, Stein-
heim, Germany) in a humidified 5% CO2, 95% air atmos-
phere.
Drug sensitivity in the A2780 and A2780cis cell lines
Cytotoxicity of cisplatin, CFDA-Pt and bafilomycin A1 in
A2780 and A2780cis cells was evaluated using an MTT-
based assay [22]. After trypsinisation, the cells were
divided in 96-well plates at concentrations of 104 cells/
well in 100 μl growth medium. The cells were allowed to
attach overnight. Then, medium was removed and stock
solutions of cisplatin in millipore water (2 mg/ml),BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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CFDA-Pt in dimethylformamide (50 mM) and bafilomy-
cin A1 in dimethylsulfoxide (100 mM) were diluted in
medium. Six subsequent dilutions each were added to the
cells in quadruplicate (100 μl/well). Some control wells
contained 0.5% dimethylformamide, which corre-
sponded to the highest solvent concentration in the dilu-
tions of CFDA-Pt. After 72 h of incubation, 50 μl of a 5
mg/ml MTT solution in phosphate buffered saline (PBS)
was added to each well, and the cells were incubated at
37°C for about 90 min. Subsequently, medium was dis-
carded and 100 μl of dimethylsulfoxide was added to each
well, yielding purple solutions. The optical density was
measured at 590 nm using a Multiskan™ microplate
reader (ThermoLabsystems, Dreieich, Germany). The
results were analysed and the pEC50 values (pEC50 = -log
EC50, EC50 is the drug concentration that produces 50% of
the maximum possible response) were determined with
the GraphPad Prism™ analysis software package (Graph-
Pad Software, San Diego, USA) using non-linear regres-
sion (sigmoidal dose response, variable slope).
Lysosomal and endosomal acidification
Acidification of lysosomal and endosomal compartments
in A2780 and A2780cis cells was compared using FITC-
dextran. Labelling of endosomes and lysosomes with
FITC-dextran was performed according to the literature
procedures [23,24]. Briefly, A2780 and A2780cis cells
were divided in a 96-well plate at concentrations of 105
cells/well in 100 μl growth medium. The cells were
allowed to attach for 6 h. Subsequently, the medium was
discarded and FITC-dextran (5 mg/ml) dissolved in
serum-free medium was added to the cells. To label endo-
somes the cells were incubated with FITC-dextran for 5
min, to label lysosomes they were incubated with FITC-
dextran for 30 min followed by washing with serum-free
medium and subsequent incubation with this medium
for 90 min. After labelling of endosomes or lysosomes,
the cells were washed with serum-free medium, and com-
plete medium was added to the cells. Fluorescence inten-
sity was measured using a Polarstar-Galaxy™ microtitre
plate reader (BMG-Lab-Technologies, Offenburg, Ger-
many).
Flow cytometry
106 cells (A2780 or A2780cis) were incubated with Lys-
oTracker™ Red DND-99 (1 μM) in RPMI-1640 for 30 min,
centrifuged, washed with the medium, and re-suspended
in normal growth medium. Then fluorescence was meas-
ured using a FACSort™ flow cytometer (BD Biosciences).
Immunohistochemical staining
Immunohistochemical staining was done one day after
seeding cells on cover slips. In some experiments, cells
were pre-treated with either 5 μM cisplatin, 5 μM CFDA-
Pt or 200 nM bafilomycin A1 for 1 h. Lysosomes were
labelled in RPMI-1640 containing 1 μg/ml LysoTracker™
Red DND-99 at 37°C for 1 h. In some experiments, nuclei
were stained with 5 μM Hoechst 33342 at 37°C for 1 h.
After three rinses with PBS, cells were fixed with 3.7% for-
maldehyde in PBS for 15 min at room temperature. After
fixation, cells were washed three times with PBS and per-
meablilised with 0.5% Triton X-100 in PBS for 30 min.
Labelling of the trans-Golgi network was performed with
5 μM NBD-C6-ceramide complexed to BSA at 37°C for 30
min. Cells were then rinsed with PBS, blocked for 1 h in
PBS containing 1% BSA followed by incubation for 90
min at 37°C with a primary antibody against the respec-
tive transport protein (ATP7A or ATP7B). Subsequently,
cells were washed with PBS and incubated for 90 min at
37°C with the secondary ALEXA Fluor™ 488- or ALEXA
Fluor™ 594-conjugated antibody. Antibody solutions
were diluted in PBS containing 1% BSA. To stain the
nucleus with propidium iodide in some samples, cells
were treated with RNAse A (100 μg/ml in PBS) for 30 min
at 37°C, washed with PBS and incubated with 5 μM pro-
pidium iodide in PBS for 15 min at 37°C. After the final
washing steps, the cells were gradually dehydrated in an
ethanol series of 70%, 90%, 100%, for 1 min each. The
cover slips were mounted in GelMount™ medium for
microscopic observations. Images showing staining of lys-
osomes with LysoTracker™ Red in both cell types are rep-
resentative each of five images, which were recorded using
an Olympus U-TBI90 confocal system at Laboratory of
Molecular Immunology, LIMES Institute, University of
Bonn. Other images in this article are each representative
of five images taken using a Leica TCS SP2 confocal system
at Laboratory for Molecular Developmental Biology,
LIMES Institute, University of Bonn. Each fluorochrome
was scanned individually and each image included 5 – 20
cells. The number of cells showing a certain pattern (e.g.
TGN localised protein) was counted in every image and
expressed as a percentage of all cells in the image. Then the
median percentage values from different images were cal-
culated.
Statistics
The significance of differences was analysed using Stu-
dent's t test or Mann-Whitney test as appropriate, p values
of <0.05 were considered significant.
Results
Sub cellular localisation of ATP7A and ATP7B
In A2780 cell line, the fluorescent signals corresponding
to ATP7A and ATP7B are limited to the perinuclear
regions of the cells (Figure 1). Previously published stud-
ies in other cell systems reported localisation of both pro-
teins in the trans-Golgi network [16-19,25,26]. However,
in cisplatin-resistant A2780cis cells the proteins are dis-
tributed away from the perinuclear region to more periph-
erally located vesicles in the cytosol (Figure 1). TheBMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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percentage of sensitive and resistant cells showing dis-
persed localisation of the proteins is given in Table 1. We
also distinguished between dividing (located next to each
other) and non-dividing cells since dividing cells are more
likely to show dispersed protein localisation. In order to
confirm localisation of ATP7A and ATP7B in the trans-
Golgi network of the sensitive cells, and re-localisation of
the transporters in the resistant cells, co-localisation
experiments using NBD-C6-ceramide, a fluorescent
marker for the Golgi complex, were performed. Images
presented in Figure 2 show substantial co-localisation of
both proteins with NBD-C6-ceramide in A2780 cells and
a negligible degree of co-localisation in A2780cis cells.
The percentage of cisplatin-sensitive and -resistant cells
that show co-localisation of the proteins with the Golgi
marker is presented in Table 2.
In order to investigate the effect of drug exposure on pro-
tein localisation, A2780 cells were treated with 5 μM cis-
platin for 1 h. Cisplatin triggered redistribution of ATP7A
and ATP7B from the perinuclear region to more peripher-
ally located sites in the cytosol. Interestingly, localisation
of both proteins in the area close to the nucleus was fully
restored within 1 h after removal of the drug from the cul-
ture medium (Figure 3). The percentage of cells, which
show dispersed localisation of the transporters in A2780
cells after cisplatin treatment and after subsequent incuba-
tion with the drug-free medium was determined, and the
values are presented in Table 3. However, since no inhib-
itors of protein synthesis were used, return of ATP7A and
ATP7B to localisation in the trans-Golgi network may or
may not reflect a retrograde traffic of the proteins.
Rapid cisplatin-induced re-localisation of ATP7A and
ATP7B towards the cell periphery and quick return of the
proteins back to the trans-Golgi network suggests that cis-
platin-controlled trafficking of the transporters may indi-
cate an efflux pathway of the drug. Cisplatin binding to
the protein may result in protein redistribution to (secre-
tory) vesicles, followed by drug excretion and re-localisa-
tion of the protein back to the trans-Golgi network.
Cisplatin exposure had no effect on protein localisation in
the resistant cell line (images not shown).
Constitutive recycling of ATP7A and ATP7B in A2780 cells
Some cellular proteins (e.g. furin and TGN38) are known
to continuously recycle between the trans-Golgi network
and the plasma membrane and to be localised in the trans-
Golgi by a process of continuous retrieval from the cell
surface [27,28]. Drugs which inhibit endosomal recycling
lead to sequestration of these proteins in vesicles of the
endosomal pathway [29,30]. In order to investigate,
whether ATP7A and ATP7B continuously recycle between
the trans-Golgi network and the cell periphery, the effect
of bafilomycin A1, a drug that blocks endosomal retrieval
by inhibiting the vacuolar H+-ATPase [31], on intracellu-
lar localisation of ATP7A and ATP7B in the sensitive
A2780 cells was studied. As shown in Figure 4, exposure
of A2780 cells to 200 nM bafilomycin A1 for 1 h triggered
redistribution of the proteins from the trans-Golgi to more
peripherally located vesicular structures. This was the case
in 77.5% cells for ATP7A and in 72.7% cells for ATP7B
(median percentage is given). These results provide evi-
dence of continuous recycling of ATP7A and ATP7B
between the Golgi apparatus and cell periphery in the sen-
sitive cells. Therefore, in the sensitive cell line the proteins
are likely to localise in the trans-Golgi network by a proc-
ess of continuous retrieval from the peripherally located
vesicles.
In order to investigate whether arrest of endosomal recy-
cling can render A2780 cells resistant to cisplatin, we
intended to assess the influence of bafilomycin A1 on cis-
platin sensitivity. Unfortunately, it was not possible
because of the adverse effect of bafilomycin A1 treatment
on cell viability. The EC50 values for bafilomycin A1 were
determined as 8.5 nM (pEC50 = 8.07 ± 0.14, mean ± SE) in
the A2780 cell line and 12 nM (pEC50 = 7.92 ± 0.1, mean
± SE) in the A2780cis cell line. However, the concentra-
tions of the drug, which do not affect cell viability (<10
nM), are not high enough to block the activity of a vacu-
olar H+-ATPase [32].
Sub cellular localisation of ATP7A and ATP7B in A2780 and  A2780cis cells Figure 1
Sub cellular localisation of ATP7A and ATP7B in 
A2780 and A2780cis cells. Immunofluorescence localisa-
tion of ATP7A and ATP7B (both green) in A2780 and 
A2780cis cells. Cell nuclei were stained with propidium 
iodide (red). Ovals indicate cell periphery. Scale bar, 10 μm.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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Comparison of lysosomal and endosomal acidification in 
A2780 and A2780cis cells
Similar protein localisation patterns in A2780 cells after
incubation with H+-ATPase inhibitor bafilomycin A1 and
in A2780cis cells suggest that defects in lysosomal/endo-
somal acidification in the A2780cis cell line may be
responsible for different localisation of ATP7A and
ATP7B. We used FITC-dextran to compare acidification of
endosomes and lysosomes in the sensitive and resistant
cells. The emission intensity of FITC at 520 nm increases
with increasing pH at λex = 485 nm but it is unaffected by
pH at λex = 460 nm. Thus, the ratio of emission intensities
at the two excitation wavelengths provides information
about acidification of a given cellular compartment,
which is independent on FITC concentration [24]. Early
endosomes were labelled with FITC-dextran in cell culture
medium for 5 min as described previously [23], and lyso-
somes were labelled with FITC-dextran for 30 min fol-
lowed by 90 min incubation with the label-free medium
following the literature procedure [24]. The ratios of FITC
emission intensities after excitation at 485 nm and 460
nm are presented in Figure 5. As is clear from Figure 5, no
notable difference in acidification of either endosomes or
lysosomes between A2780 and A2780cis cells was
observed.
Co-localisation of ATP7A and ATP7B with a trans-Golgi network marker Figure 2
Co-localisation of ATP7A and ATP7B with a trans-Golgi network marker. Co-localisation of markers for ATP7A and 
ATP7B (both red) with NBD-C6-ceramide (green), a marker for the trans-Golgi network. Yellow, the structure is positive for 
Golgi and protein markers. Ovals indicate cell periphery. Scale bar, 10 μm.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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Reduced lysosomal compartment in cisplatin-resistant 
cells
The lysosomal dye LysoTracker™ Red DND-99 was used to
compare lysosomal compartments in the A2780 and
A2780cis cell lines. This lysosomal dye has been chosen
for its ability to be retained in acidic organelles after for-
maldehyde fixation. Images of sensitive and resistant cells
in which lysosomes were stained with LysoTracker™ Red
and nuclei were labelled with Hoechst 33342 are pre-
sented in Figure 6A and show that cisplatin-resistant cells
contain notably less acidic vesicles compared to their sen-
sitive counterparts. This observation was confirmed by a
flow cytometry study. Average fluorescence intensity of
the lysosomal dye per cell was significantly lower in the
resistant cell line indicating a reduced lysosomal compart-
ment (Figure 6B).
Co-localisation of ATP7A and ATP7B with a fluorescent 
cisplatin analogue
In order to reveal whether ATP7A and ATP7B mediate cis-
platin transport in A2780 and A2780cis cells, co-localisa-
tion experiments using a fluorescent cisplatin analogue
labelled with carboxyfluorescein-diacetate (CFDA-Pt, Fig-
ure 7A) were performed. Earlier studies reported that
accumulation of CFDA-Pt is lower in cisplatin-resistant
cells in parallel to decreased cisplatin uptake in these cells
as compared to their sensitive counterparts [33]. In addi-
tion, the cellular distribution pattern of CFDA-Pt was
found to be significantly different to that of the platinum-
free 1-([5-(and-6)-carboxyfluorescein diacetate]-2-(tert-
butyloxycarbonyl)-1,2-ethylenediamine (CFDA-Boc,
chemical structure is depicted in Figure 7A), indicating
that the intracellular trafficking of CFDA-Pt is determined
by the platinum moiety and not by the fluorescent label
[21]. These results suggested that CFDA-Pt represents a
suitable model compound for investigation of the cellular
processing of cisplatin. However, antitumor activity of
this complex had not been investigated, so in order to val-
idate suitability of CFDA-Pt for our cellular system, we
compared cytotoxicity of CFDA-Pt and cisplatin in A2780
and A2780cis cells. As presented in Table 4, CFDA-Pt was
found to be less cytotoxic than cisplatin in both cell lines.
Nevertheless, it exhibited substantial activity in A2780
cells and its activity was significantly reduced in the
A2780cis cell line indicating that cisplatin-resistant cells
are also resistant to CFDA-Pt (~4-fold resistance). These
data provide evidence that CFDA-Pt can be used as a
model complex in fluorescence microscopy investigations
of intracellular distribution of cisplatin.
Images of A2780 and A2780cis cells incubated with
CFDA-Pt and subsequently stained with antibodies to
ATP7A and ATP7B are presented in Figure 7B. In the sen-
sitive cells, both proteins showed extensive co-localisation
Localisation of ATP7A and ATP7B in A2780 cells after cispla- tin exposure Figure 3
Localisation of ATP7A and ATP7B in A2780 cells 
after cisplatin exposure. Immunofluorescence localisation 
of ATP7A and ATP7B (both green) in A2780 cells after cispla-
tin exposure for 1 h and subsequent incubation of the cells in 
the drug-free medium for 1 h. Cell nuclei were stained with 
propidium iodide (red). Ovals indicate cell periphery. Scale 
bar, 10 μm.
Table 2: Median percentage of A2780 and A2780cis cells showing 
co-localisation of ATP7A and ATP7B with the Golgi marker.
A2780 A2780cis p
ATP7A 92.8 0.0 0.0159
ATP7B 88.9 15.4 0.0079
Median percentage values were calculated from five individual images. 
The significance of differences was analysed using Mann-Whitney test.
Table 1: Median percentage of A2780 and A2780cis cells showing dispersed localisation of ATP7A and ATP7B.
Cell line All cells p Dividing cells p (div. cells) Non-dividing cells p (non-div. cells)
A2780 16.2 20.0 0
ATP7A A2780cis 88.8 0.0286 82.6 0.0286 100.0 0.0286
A2780 11.1 12.5 10
ATP7B A2780cis 80.2 0.0286 82.5 0.0286 80 0.0286
Median percentage values were calculated from five individual images. The significance of differences was analysed using Mann-Whitney test.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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with CFDA-Pt. In the resistant cells, however, only ATP7A,
and not ATP7B, co-localised with the fluorescent cisplatin
analogue. Thus, both proteins are likely to mediate trans-
port of CFDA-Pt in the A2780 cells but only ATP7A seems
to be involved in transport of the drug in A2780cis cells.
Interestingly, after the treatment with CFDA-Pt both
ATP7A and ATP7B showed dispersed localisation in
A2780 cells and this may indicate that CFDA-Pt induces
re-localisation of the transporters to the cell periphery in
the sensitive cells in the same way as cisplatin does. How-
ever, images in Figure7B do not present sufficient proof of
protein re-localisation following exposure to CFDA-Pt.
Discussion
Sub cellular localisation of ATP7A and ATP7B in sensitive 
and resistant cells
In previous work from our laboratory, we assessed the role
of copper homeostasis proteins CTR1, ATP7A and ATP7B
in uptake and efflux of cisplatin in A2780 human ovarian
carcinoma cell line and its cisplatin-resistant variant
A2780cis cell line as well as the relevance of these trans-
porters for tumour cell sensitivity to cisplatin [20]. Intrac-
ellular accumulation of cisplatin was found to be
markedly reduced in the resistant A2780cis cell line,
which is likely to result (al least in part) from the
decreased expression of CTR1, a copper influx transporter
believed to mediate cisplatin uptake. However, no differ-
ence in the rate of cisplatin efflux between sensitive and
resistant cell line was observed, although resistant cells
overexpressed the efflux transporter ATP7A. Expression of
ATP7B, another transport protein previously reported to
be involved in cisplatin efflux, was comparable in sensi-
tive and resistant cells. This finding correlated well with
similar efflux rates in both cell lines, however, it did not
agree with the results of other groups, which linked
increased expression of ATP7B to cisplatin resistance in
different clonal cell lines [10,11].
In an attempt to understand these contradictions, we
examined the sub cellular localisation of ATP7A and
ATP7B in A2780 sensitive and A2780cis resistant cells.
Our results show that both proteins have different locali-
sation patterns in A2780 and A2780cis cells. In the sensi-
tive cells, both transporters localise in the trans-Golgi
network, which is consistent with the previously reported
observations in a number of other cell lines [16-
19,25,26]. However, in the resistant cells, ATP7A and
ATP7B are distributed away from the trans-Golgi network
to more peripherally located vesicles in the cytosol. It is
not clear, to which cellular compartments these vesicles
belong. It is not likely that ATP7A and ATP7B are re-local-
ised to the lysosomal compartment given that the latter is
significantly reduced in A2780cis cells. Both ATP7A and
ATP7B have been previously suggested to accumulate cis-
platin in vesicles of the secretory pathway [10,18,34].
However, the possibility that the transporters are localised
Comparison of lysosomal and endosomal acidification Figure 5
Comparison of lysosomal and endosomal acidifica-
tion. Comparison of lysosomal and endosomal acidification 
in A2780 and A2780cis cells using ratios of emission intensi-
ties at 520 nm at the two excitation wavelengths (485 nm 
and 460 nm) after FITC-dextran labelling of endosomes and 
lysosomes, respectively. The results are expressed as means 
± SE of emission intensity ratios in 24 wells (endosomes) and 
48 wells (lysosomes) from two independent experiments. 
The significance of differences was analysed using Student's t 
test.
Table 3: Median percentage of A2780 cells showing dispersed 
localisation of ATP7A and ATP7B after cisplatin exposure and 
after subsequent incubation with the drug-free medium.
Cisplatin exposure 1 h after drug removal p
ATP7A 76.5 10.5 0.0043
ATP7B 70.8 12.2 0.0043
Median percentage values were calculated from five individual images. 
The significance of differences was analysed using Mann-Whitney test.
Effect of bafilomycin A1 on localisation of ATP7A and ATP7B Figure 4
Effect of bafilomycin A1 on localisation of ATP7A and 
ATP7B. Immunofluorescence localisation of ATP7A and 
ATP7B (both green) in A2780 cells treated with 200 nM 
bafilomycin A1 for 1 h. Cell nuclei were stained with propid-
ium iodide (red). Ovals indicate cell periphery. Scale bar, 10 
μm.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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in vesicles of the endosomal compartment can not be
ruled out. In any event, it should be pointed out that vesic-
ular structures expressing ATP7A in the A2780cis cell line
do not express ATP7B and vice versa, since ATP7A-con-
taining vesicles co-localise with a fluorescent cisplatin
analogue CFDA-Pt while vesicles containing ATP7B do
not.
In A2780 cells, both transporters appear to undergo con-
stitutive recycling between the trans-Golgi network and
more peripherally located vesicles in the cytosol. Cisplatin
exposure triggers rapid trafficking of ATP7A and ATP7B
from the Golgi complex towards the cell periphery. The
observed shift in steady-state distribution of the proteins
is reversible upon removal of cisplatin from the culture
medium. This system of cisplatin-regulated trafficking of
ATP7A and ATP7B may indicate how cisplatin efflux by
these transporters is achieved. In fact, both proteins have
been reported to undergo copper-regulated trafficking
between the trans-Golgi network and the plasma mem-
brane (ATP7A) or vesicular structures at the cell periphery
(ATP7B) as a way to maintain copper homeostasis [15-
17]. Copper-induced trafficking of ATP7A and ATP7B was
also observed in A2780 cells (images not shown). How-
ever, in our study it was not possible to distinguish
between the sites of ATP7A and ATP7B re-localisation
after treatment with copper or cisplatin. Thus, our results
suggest that A2780 cells utilise the same vesicular export
pathway for efflux of cisplatin as they employ for export
of copper.
Co-localisation of ATP7A and ATP7B with CFDA-Pt Figure 7
Co-localisation of ATP7A and ATP7B with CFDA-Pt. 
A. Structure of the fluorescent cisplatin analogue (CFDA-Pt) 
and the platinum-free fluorescein derivative (CFDA-Boc). B. 
Co-localisation of CFDA-Pt (green) and markers for ATP7A 
and ATP7B (both red) in A2780 and A2780cis cells. Yellow, 
the structure is positive for CFDA-Pt and protein markers. 
Ovals indicate cell periphery. Scale bar, 10 μm.
Lysosomal compartments in A2780 and A2780cis cells Figure 6
Lysosomal compartments in A2780 and A2780cis 
cells. Comparison of the lysosomal compartments in A2780 
and A2780cis cells using confocal microscopy (A) and flow 
cytometry (B). A. Lysosomes were labelled with Lys-
oTracker™ Red (red), cell nuclei were stained with Hoechst 
33342 (blue). Ovals indicate cell periphery. Scale bar, 5 μm. B. 
The results represent means ± SE of four experiments. The 
significance of differences was analysed using Student's t test.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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Possible causes of altered localisation of transporters in 
resistant cells
Continuous recycling of the copper efflux transporters
between the Golgi complex and peripherally located vesi-
cles in the cytosol appears to be blocked in the cisplatin-
resistant A2780cis cell line. As a result, the proteins are
sequestrated in vesicular structures in the cytosol. Looking
for possible cellular alterations, which may account for
different localisation of ATP7A and ATP7B in the resistant
cells, we compared acidification of the lysosomal and
endosomal compartment in A2780 and A2780cis cell
lines. Vesicular trafficking and protein turnover are very
sensitive to even small changes in organelle pH and we
hypothesised that altered localisation of ATP7A and
ATP7B in the resistant cells may be a consequence of acid-
ification defects of the lysosomal and/or endosomal com-
partment. Some cisplatin-resistant cell lines have
previously been reported to have less acidic lysosomes
than their sensitive counterparts [35-38]. However, no
notable differences in acidification of either lysosomes or
endosomes between sensitive and resistant cells were
observed in our case.
Interestingly, the cisplatin-resistant A2780cis cells were
found to have significantly less lysosomes than the sensi-
tive A2780 cells. Lysosomes play an important role in the
vesicular trafficking [39]. They represent a terminal degra-
dative compartment of the endocytic pathway. Lysosomes
receive their enzymes from the trans-Golgi network
mainly  via  late endosomes (also called multivesicular
bodies), which also sort internalised proteins for recycling
or degradation in lysosomes [40]. Unfortunately, the
mechanism of delivery of endocytosed material from
endosomes to lysosomes is not well elucidated [41]. Sev-
eral possible pathways have been proposed [41] including
maturation of late endosomes into lysosomes, vesicular
transport from late endosomes to lysosomes, so-called
'kiss-and-run' (a cycle of transient contacts between endo-
somes and lysosomes, which allow exchange of the mate-
rial between them, followed by dissociation) and direct
fusion to form a hybrid organelle, which contains both
late endosome and lysosome components and where the
endocytic cargo is either recycled or digested. Any of these
mechanisms represent a sequence of highly regulated
intracellular events and even small alterations may lead to
the failure of the whole pathway to function properly. A
reduction of the lysosomal compartment in the cisplatin-
resistant cell line may indicate decreased protein traffick-
ing from late endosomes to lysosomes due to mis-sorting
of proteins in late endosomes and may reflect a general
defect in intracellular protein trafficking, which may pre-
vent constitutive recycling of ATP7A and ATP7B and even-
tually lead to sequestration of these transporters in the
vesicular structures of resistant cells. Our results confirm
findings of other groups, that the lysosomal compartment
in cells with acquired resistance to cisplatin features major
abnormalities, which eventually results in changes in pro-
tein processing [35-37,42]. We suggest that the reduced
lysosomal compartment may reflect defects in protein
recycling, which may in turn be responsible for altered
localisation of the efflux transporters ATP7A and ATP7B
in the A2780cis resistant cell line.
Consequences of altered localisation of the transporters in 
resistant cells
In order to investigate possible consequences of altered
localisation of ATP7A and ATP7B, co-localisation experi-
ments using a fluorescent cisplatin analogue modified
with carboxyfluorescein-diacetate (CFDA-Pt) were carried
out. Some reports in the literature [6,43] argue that CFDA-
Pt is not likely to behave similarly to cisplatin inside the
cell because a large lipophilic fluorophore would signifi-
cantly change the pharmacokinetic properties of the com-
plex. However, there are several lines of evidence that
CFDA-Pt represents a suitable model complex for investi-
gation of intracellular transport of cisplatin. Firstly, the
cellular distribution of CFDA-Pt was found different from
that of the platinum-free fluorophore CFDA-Boc [21,33].
Secondly, cellular accumulation of CFDA-Pt in cisplatin-
resistant U2-OS/Pt osteosarcoma cells was found to be
reduced compared to its accumulation in sensitive U2-OS
cells [33], which is in agreement with decreased cisplatin
accumulation in the U2-OS/Pt cell line [33,44]. Finally,
the results of the cytotoxicity tests presented here show
that CFDA-Pt exhibits substantial activity in the A2780
cell line and cross-resistance with cisplatin in the
A2780cis cell line. Taken together, these findings strongly
suggest that modification of cisplatin with carboxyfluores-
Table 4: Sensitivity of A2780 and A2780cis cells to cisplatin and CFDA-Pt.
A2780 A2780cis
pEC50 EC50, μMp E C 50 EC50, μMp
cisplatin 5.455 ± 0.0941 3.5 4.631 ± 0.0095 23.4 0.0001
CFDA-Pt 4.445 ± 0.1524 35.9 3.856 ± 0.0711 139.3 0.0127
Sensitivity of A2780 and A2780cis cells to cisplatin and CFDA-Pt was assessed using an MTT-based assay. The pEC50 values are means ± SE of four 
experiments. The significance of differences was analysed using Student's t test.BMC Cancer 2008, 8:175 http://www.biomedcentral.com/1471-2407/8/175
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cein-diacetate does not alter the pharmacological proper-
ties of the complex, which are important for the cisplatin-
resistant phenotype.
Co-localisation experiments showed that CFDA-Pt is asso-
ciated with ATP7A and ATP7B in cisplatin-sensitive A2780
cells. Both transporters have been previously reported to
co-localise with a fluorescein-labelled cisplatin analogue
in vesicles of the secretory pathway [18,34]. Based on the
data obtained using different transfected cell lines it has
been suggested that ATP7B mediates cisplatin efflux,
whereas ATP7A functions to sequester the drug in the
vesicular compartment [12]. On the contrary, in the
A2780 cell line both proteins appear to be involved in cis-
platin efflux, since cisplatin triggers trafficking of both
transporters away from the trans-Golgi network to vesicu-
lar compartments on the cell periphery. It should, how-
ever, be pointed out that the cell lines transfected with
ATP7A and ATP7B exhibited biologically relevant degree
of cisplatin resistance and cannot, therefore, be directly
compared with cisplatin-sensitive cell lines. Otherwise,
since cisplatin serves as a substrate for both ATP7A and
ATP7B, it is also possible that the presence of considerable
amounts of both transporters in the cell in some way
influences their function, which is not the case in a clonal
cell line engineered to overexpress one of the proteins.
In the cisplatin-resistant cell line, ATP7A was found to co-
localise with CFDA-Pt, and only a negligible degree of co-
localisation between the complex and ATP7B was
observed. Therefore, in spite of altered localisation ATP7A
appears to mediate either efflux or sequestration of cispl-
atin in the A2780cis cells. Sequestration is more likely to
take place given higher expression of the transporter in the
resistant cell line and nonetheless similar efflux rate in
both cell lines [20]. It is also in agreement with previously
reported data, which suggested that ATP7A regulates cell
sensitivity to cisplatin by sequestrating it in the vesicular
compartment [11,12]. In contrast, re-localisation of
ATP7B away from the trans-Golgi network to peripherally
located vesicles appears to prevent cisplatin binding to
this protein and does not allow ATP7B to perform cispla-
tin efflux in the resistant cells. As a result, the drug
becomes sequestrated intracellularly, possibly in ATP7A-
expressing vesicles.
In the sensitive A2780 cells, both ATP7A and ATP7B are
likely to mediate cisplatin transport. Due to altered local-
isation of the proteins in the resistant A2780cis cell line,
ATP7A appears to dominate over ATP7B in cisplatin bind-
ing and to determine the intracellular fate of the drug. This
is in agreement with increased expression of ATP7A and
unchanged expression levels of ATP7B in resistant cells
compared to their sensitive counterparts [20]. Given
peripheral localisation of ATP7A in A2780cis cells, cispla-
tin may encounter this protein directly after it enters the
cell, which may subsequently result in cisplatin sequestra-
tion in ATP7A-expressing vesicles and therefore prevent its
binding to nuclear DNA. This is supported by the previous
findings that cellular accumulation of cisplatin is 2.5
times lower in the A2780cis cell line compared to the
A2780 cell line, while DNA platination is, on average,
reduced 5.4-fold [20]. It should be noted, however, that
other factors such as increased glutathione levels in the
A2780cis cell line (Zisowsky et al., unpublished data) are
also involved in regulating intracellular transport of cispl-
atin and cisplatin sensitivity of A2780cis cells.
Conclusion
Taken together, our results suggest that changes in sub cel-
lular localisation of copper efflux transporters may
account for acquired resistance to cisplatin. Altered local-
isation of ATP7A and ATP7B in A2780cis cells is likely to
result from a general defect in intracellular protein recy-
cling, which may be related to the reduced lysosomal
compartment in this cell line. Earlier studies have indi-
cated that accumulation of cisplatin in the secretory path-
way may require lysosomal function. Abnormalities in
structure and function of the lysosomal compartment
may promote sequestration of cisplatin away from its
pharmacological target, nuclear DNA, due to incorrect
localisation of transport proteins.
The results of the present study further indicate that sub
cellular localisation of transport proteins can serve as a
marker for detection of clinically relevant cisplatin resist-
ance. Using modern imaging technology it should be pos-
sible to identify resistant tumours at an early stage of
chemotherapy and to adjust the treatment accordingly. In
order to validate this approach, further studies should
focus on the transporter localisation in tumour cells iso-
lated from different patients and correlation of protein
localisation patterns with clinical response to cisplatin
chemotherapy. The results may contribute to the develop-
ment of new individualised therapeutic strategies in cispl-
atin treatment of ovarian carcinoma.
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